Treatment of experimental listeriosis by CI 934, a new quinolone.
CI 934, a new quinolone, is only marginally more active in vitro against Listeria monocytogenes and other Listeria spp. than ciprofloxacin. A bactericidal effect is seen only after several hours of incubation. However, mice infected with a virulent strain of L. monocytogenes were protected by parenteral treatment with CI 934. With a dosage of 2 x 2 mg CI 934 per day for three days almost complete remission could be achieved. These results are somewhat better than those obtained in previous experiments with other antibiotics.
Hof
H
H
Institute of Medical Microbiology and Hygiene, University of Heidelberg, FRG.
D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D024841:Fluoroquinolones; D008089:Listeria monocytogenes / Q000502:physiology; D008088:Listeriosis / Q000188:drug therapy*; D008826:Microbial Sensitivity Tests
D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; C047718:CI 934